GARDP Welcomes Renewed G7 Call For Greater Investments and Action to Address Antimicrobial Resistance


13 Dec 2021

The Global Antibiotic Research and Development Partnership (GARDP) welcomed the statement by the G7 Finance Ministers today, which reiterated their call for greater investments and action to address antimicrobial resistance (AMR), a silent pandemic of drug-resistant infections. In their statement the finance ministers highlighted GARDP’s role to ‘promote antibiotic development, access, and stewardship including in low- and middle-income countries.’

The United Kingdom, which holds the Presidency of the G7 in 2021, has long been a global leader in both calling attention to AMR and putting forward concrete solutions and recommendations to galvanize international action. This has included the UK government’s role as a key partner and funder of GARDP, including its on-going support for the development of new and improved treatments for drug-resistant infections that pose the greatest threat to health as well as during the setting up of SECURE.

About GARDP

The Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. GARDP was created by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) in 2016 to ensure that everyone who needs antibiotics receives effective and affordable treatment. We aim to develop five new treatments by 2025 to fight drug-resistant infections. GARDP is funded by the governments of Germany, Japan, Luxembourg, Monaco, Netherlands, South Africa, Switzerland, United Kingdom, as well as Médecins Sans Frontières and private foundations.


We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.